Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Myeloma Crowd Radio/MCRI: Dr. Carmen Baldino, PhD and Dr. Kelvin Lee, MD

  • Broadcast in Health
Myeloma Crowd Radio

Myeloma Crowd Radio


Follow This Show

If you liked this show, you should follow Myeloma Crowd Radio.

Patients who have high-risk genetic features like the 14;16 translocation need new treatment options. Dr. Carmen Baldino of Jasco Pharmaceuticals and Dr. Kelvin Lee of the Roswell Park Cancer Institute are working on a potentially curative solution for patients with this high-risk translocation using a PIM2 Kinase inhibitor called JP-11646. Learn more about this proposal for the Myeloma Crowd Research Initiative to address the unmet needs for high-risk patients.